Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypnozoite Biomarkers and Relapse Patterns in P. vivax
NCT04228315Unknown
- Sponsor
- Armed Forces Research Institute of Medical Sciences
- Start
- Nov 2019
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of primaquine in Plasmodium vivax malaria (3 arms), sponsored by Armed Forces Research Institute of Medical Sciences. Primary endpoints: Therapeutic efficacy of a radical cure course of primaquine at 6 months and Build a biorepository of prospectively collected blood and urine samples at 6 months. Status: unknown.
02
Drugs
primaquine
03
Conditions
Plasmodium vivax malaria
Beyond the preview
Go deeper on NCT04228315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04228315.